, Seoul, October 28 (Reporter Zeng Nai) "China-Korea Biomedical Industry Special Online Exchange Conference" was held in Seoul on the 28th.

  In the face of the epidemic, this online exchange meeting is a new measure taken by the Industry Committee of the Investment Promotion Agency of the Ministry of Commerce of China and foreign agencies to strengthen the connection between China and South Korea's biomedical industry resources and promote cross-border exchanges between enterprises.

The online exchange meeting was held in Beijing and Seoul on October 23 and 28 respectively.

  On the 28th, Gu Jinsheng, Minister Counsellor of the Economic and Commercial Office of the Chinese Embassy in South Korea, said in a video speech that in recent years, the Korean medical industry has developed rapidly and has become one of the emerging pillar industries in South Korea, especially in the field of biomedicine.

  Data show that from 2009 to 2019, the average annual growth rate of South Korea's biomedical output reached 8.13%.

The trade cooperation between China and South Korea in this field has grown steadily: In 2018, the trade volume of China and South Korea in the field of medicine reached 1.14 billion U.S. dollars, and China has been the third largest country of medicine trade in South Korea for many years.

  Gu Jinsheng said that this online exchange meeting is a useful attempt to promote and develop economic and trade cooperation between China and South Korea. Looking ahead, China and South Korea have broad prospects for cooperation in the fields of medicine.

  Yu Xiaojia, director of the Korea Office of the Investment Promotion Agency of the Ministry of Commerce of the People’s Republic of China, also said: “China and South Korea have great potential for cooperation in biomedicine and general health industries.” She introduced that from the perspective of China’s biomedical industry, foreign-invested enterprises, special It is a multinational company that has strongly promoted the technological progress of China's pharmaceutical industry and promoted the adjustment of the industrial structure; in 2019, the absorption of foreign capital in the pharmaceutical manufacturing industry increased by 61.3% year-on-year.

  In response to this exchange meeting, Yu Xiaojia introduced that 4 well-known Chinese and Korean biomedical companies and 3 integrated professional entity teams of biomedical industry colleges were selected from Beijing and Zhejiang, China, Seoul, Gyeonggi, and Jeollabukdo. , Concentrate Korean traditional medicine and modern medicine industry, education and research elite team, high-quality listed companies.

  She said that in the future, the "China-Korea Investment Promotion Online Project Docking Platform" will continue to improve its service level and provide Chinese and Korean entrepreneurs with key industries and online project promotion and docking services in key regions.

  According to Wang Ke, deputy director of Ningbo Investment Promotion Center, South Korea has always been an important source of foreign investment in Ningbo. As of the end of September 2020, South Korea has established a total of 426 foreign-invested enterprises in Ningbo with a total investment of 2.88 billion US dollars; Ningbo enterprises established in South Korea There are also more than 60.

  Wang Ke said that Ningbo is actively building modern industrial clusters. The biopharmaceutical industry is a strategic emerging industry that Ningbo focuses on developing. He looks forward to further deepening the exchanges and cooperation between Ningbo and South Korean biopharmaceutical companies.

  Yoo Jae-won, vice president of the Korea Trade Promotion Corporation, said that the biomedical health industry has achieved a growth of more than 10 times in the past ten years, which can be called a sunrise industry in the future.

He believes that it is timely to seek a new model of cooperation between the two countries in this field through this exchange meeting; especially in the current situation of inconvenience in exchanges due to the epidemic, it is necessary to seek the development of traditional medicine projects between the two countries and the business of the pharmaceutical industry through the Internet. Cooperation is a new business activity model facing the future.

  When the antenna exchange meeting attracted many well-known companies from China and South Korea, including Beijing Tongrentang, Ningbo Bio-industrial Park, Ningbo Life Science City, Korea Won Kwang Foundation, Samsung Nursing Home, Kyung Hee University Institute of Korean Medicine, Korea Myongji University School of Medicine, Korea GENECELL, GENNBIO Biotechnology Company, Seoul Guro Non-Contact Medical Technology Company, etc.

  According to reports, the Korean Won Kwang Group Urban Elderly Complex Project, the Korean Medicine Institute of Kyung Hee University’s Antiviral New Drug Project, GenNBio’s Allogeneic Organ Transplant Industrialization Project, and the Seoul Guro non-contact diagnosis and treatment project have been reached online with Chinese companies and parks. Initial cooperation intention.

  In addition, the Biomedical Industry Committee of the Investment Promotion Agency of the Ministry of Commerce, Beijing Tongrentang, and Ningbo Life Science City also set up "cloud booths" during the "First Korea International Biomedicine Cloud Exhibition", and held a "cloud exhibition" and "cloud docking" "Combined innovative services will build a new platform for Chinese and Korean companies and industrial parks that cannot communicate directly during the epidemic, and create new business opportunities for cross-border exchanges between Chinese and Korean companies.

  The online exchange meeting was jointly sponsored by the Biomedical Industry Committee of the Investment Promotion Agency of the Ministry of Commerce, the Korea Office of the Investment Promotion Agency of the Ministry of Commerce and the Ningbo Investment Promotion Center.